299 related articles for article (PubMed ID: 11698449)
1. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
2. Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).
Young KA; Chen XS; Holers VM; Hannan JP
J Biol Chem; 2007 Dec; 282(50):36614-25. PubMed ID: 17925391
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
[TBL] [Abstract][Full Text] [Related]
4. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.
Guthridge JM; Rakstang JK; Young KA; Hinshelwood J; Aslam M; Robertson A; Gipson MG; Sarrias MR; Moore WT; Meagher M; Karp D; Lambris JD; Perkins SJ; Holers VM
Biochemistry; 2001 May; 40(20):5931-41. PubMed ID: 11352728
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3. An initial model of ligand interaction with two linked short consensus repeat modules.
Molina H; Perkins SJ; Guthridge J; Gorka J; Kinoshita T; Holers VM
J Immunol; 1995 May; 154(10):5426-35. PubMed ID: 7730644
[TBL] [Abstract][Full Text] [Related]
6. Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2009 Apr; 284(14):9513-20. PubMed ID: 19164292
[TBL] [Abstract][Full Text] [Related]
7. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
Asokan R; Hua J; Young KA; Gould HJ; Hannan JP; Kraus DM; Szakonyi G; Grundy GJ; Chen XS; Crow MK; Holers VM
J Immunol; 2006 Jul; 177(1):383-94. PubMed ID: 16785534
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
Clemenza L; Isenman DE
J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d.
Hannan JP; Young KA; Guthridge JM; Asokan R; Szakonyi G; Chen XS; Holers VM
J Mol Biol; 2005 Feb; 346(3):845-58. PubMed ID: 15713467
[TBL] [Abstract][Full Text] [Related]
10. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure.
Isenman DE; Leung E; Mackay JD; Bagby S; van den Elsen JM
J Immunol; 2010 Feb; 184(4):1946-55. PubMed ID: 20083651
[TBL] [Abstract][Full Text] [Related]
11. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).
Prodinger WM; Schwendinger MG; Schoch J; Köchle M; Larcher C; Dierich MP
J Immunol; 1998 Nov; 161(9):4604-10. PubMed ID: 9794388
[TBL] [Abstract][Full Text] [Related]
12. Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
Kovacs JM; Hannan JP; Eisenmesser EZ; Holers VM
J Biol Chem; 2010 Aug; 285(35):27251-27258. PubMed ID: 20558730
[TBL] [Abstract][Full Text] [Related]
13. Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking.
Shaw CD; Storek MJ; Young KA; Kovacs JM; Thurman JM; Holers VM; Hannan JP
J Mol Biol; 2010 Dec; 404(4):697-710. PubMed ID: 20951140
[TBL] [Abstract][Full Text] [Related]
14. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC; Myones BL; Frazier B; Holers VM
J Biol Chem; 1990 Jul; 265(21):12293-9. PubMed ID: 1695627
[TBL] [Abstract][Full Text] [Related]
15. Structure of complement receptor 2 in complex with its C3d ligand.
Szakonyi G; Guthridge JM; Li D; Young K; Holers VM; Chen XS
Science; 2001 Jun; 292(5522):1725-8. PubMed ID: 11387479
[TBL] [Abstract][Full Text] [Related]
16. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.
Molina H; Kinoshita T; Webster CB; Holers VM
J Immunol; 1994 Jul; 153(2):789-95. PubMed ID: 8021513
[TBL] [Abstract][Full Text] [Related]
17. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
18. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21).
Hannan JP
Curr Protein Pept Sci; 2016; 17(5):463-87. PubMed ID: 26916158
[TBL] [Abstract][Full Text] [Related]
19. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.
Lambris JD; Ganu VS; Hirani S; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4235-9. PubMed ID: 2408276
[TBL] [Abstract][Full Text] [Related]
20. Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study.
Gilbert HE; Eaton JT; Hannan JP; Holers VM; Perkins SJ
J Mol Biol; 2005 Feb; 346(3):859-73. PubMed ID: 15713468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
